Using spleen stiffness measurement to predict outcomes in liver disease patients with acute liver injury

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study utilizes a non-invasive tool called spleen stiffness measurement (SSM) to monitor disease progression in inpatients suffering from chronic liver disease (CLD) and acute liver injury. The goal is to establish an early warning model for acute-on-chronic liver failure (ACLF) and to assess how changes in SSM can impact short-term patient outcomes, including morbidity and mortality over 28 and 90 days. By focusing on the relationship between portal hypertension and liver failure, the study aims to provide valuable insights into managing these serious conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 years and 80 years
2. Chronic liver diseases regardless of etiology
3. Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement

Exclusion Criteria:

1. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization
2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission
3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases
4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period
5. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)
6. The pregnant
7. Jaundice due to biliary obstruction or cholestasis
8. Unsuitable to participate in this study judging by investigators

Where it's running

• Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Jinjun Chen, PHD — Nanfang Hospital, Southern Medical University
• Study coordinator: Jinjun Chen, PHD
• Email: chjj@smu.edu.cn
• Phone: 86-18588531001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS

  A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.

  Recruiting Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07799948

• Austrian PBC Registry

  This registry follows adults with primary biliary cholangitis in Austrian centers to see how the disease develops over time and how biomarkers relate to complications and symptoms.

  Recruiting Medical University of Vienna · Klagenfurt, Carinthia and 10 other locations · NCT07598669

• Even protein distribution plus exercise for people awaiting liver transplant

  This trial tests whether spreading daily protein evenly and combining it with a 12-week exercise program improves nutrition, muscle mass, and function in people waiting for a liver transplant compared with uneven protein timing or usual advice.

  Recruiting at 2 sites Agricultural University of Athens · Athens, Attica and 1 other locations · NCT07561138

• 4D-Flow MRI to see portal hypertension and TIPS outcomes in cirrhosis

  This study tests a noninvasive 4D-Flow MRI method to see if it can safely and reliably reflect portal hypertension and predict outcomes for people with cirrhosis, including those needing a TIPS procedure.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07554183

• Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis

  This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.

  Recruiting Phase 4 Asian Institute Of Medical Sciences · Hyderābād, Sindh · NCT07521332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.